Abstract
Epilepsy is a diverse and often severe neurological disorder characterized by frequent and unpredictable seizures caused by the simultaneous discharge of brain cells in one or both hemispheres. Recently, there has been a significant shift in the approach to healthcare, moving from a standardized model to a more personalized and targeted model. This transformation has been made possible by advances in pharmacogenomics. It has great potential in customizing treatments based on the specific needs of patients, and this is particularly evident in the management of epilepsy. With ongoing research, the development of comprehensive genetic databases, and the integration of pharmacogenomics into clinical practice using artificial intelligence, a brighter future can be expected for personalized epilepsy treatment. Using the potential of pharmacogenomics, we can expect to provide the best possible care for epilepsy patients and improve their quality of life.